CSIMarket
 
Idexx Laboratories Inc  (IDXX)
Other Ticker:  
 
 
Price: $529.7700 $-5.81 -1.085%
Day's High: $536.854 Week Perf: -3.38 %
Day's Low: $ 526.73 30 Day Perf: -5.49 %
Volume (M): 829 52 Wk High: $ 583.39
Volume (M$): $ 439,338 52 Wk Avg: $496.45
Open: $530.12 52 Wk Low: $372.50



 Market Capitalization (Millions $) 44,501
 Shares Outstanding (Millions) 84
 Employees 10,350
 Revenues (TTM) (Millions $) 3,660
 Net Income (TTM) (Millions $) 845
 Cash Flow (TTM) (Millions $) 341
 Capital Exp. (TTM) (Millions $) 134

Idexx Laboratories Inc
IDEXX Laboratories Inc.
is a global company that provides diagnostics, software, and solutions for the veterinary, livestock, and poultry industries.
It was founded in 1983 and is headquartered in Westbrook, Maine, United States.
The company develops and manufactures a wide range of products, including diagnostic tests, point-of-care analyzers, imaging systems, and software solutions, which help veterinarians diagnose, treat, and manage diseases in animals.
IDEXX has an extensive product portfolio, which includes tests for detecting infectious diseases such as parvovirus, Lyme disease, and feline leukemia, as well as tests for monitoring organ and blood functions in animals.
Its point-of-care analyzers, such as the IDEXX VetLab Station and IDEXX SNAP Pro Analyzer, provide fast and accurate results, enabling veterinarians to make quick and informed decisions regarding animal care.
Moreover, IDEXX Laboratories Inc.
provides software solutions that help veterinary practices manage their operations, billing, and patient records.
IDEXX Neo is a cloud-based practice management software that streamlines workflow, improves communication with clients, and enhances patient care.
IDEXX Laboratories Inc.
operates in more than 175 countries and has over 9,000 employees worldwide.
It generates over $2 billion in revenue annually and has consistently been ranked as one of the best places to work in the United States.
The company's commitment to research and development has resulted in many innovative products and solutions, making it a leader in animal healthcare.


   Company Address: One IDEXX Drive Westbrook, 4092 ME
   Company Phone Number: 556-0300   Stock Exchange / Ticker: NASDAQ IDXX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Idexx Laboratories Inc

In Vitro & In Vivo Diagnostic Substances Company Reports Strong Revenue Growth in Q4 20232.

The financial results of Idexx Laboratories Inc for the fourth quarter of 2023 paint a mixed picture of their performance. On one hand, the company saw a significant increase in revenue of 8.762% to $901.16 million compared to the previous year. This growth is a positive sign of the company's ability to generate more income and attract more customers.
Similarly, the increase in EPS by 11.69% to $2.32 per share is also a good indicator of the company's profitability and efficiency in managing costs. These numbers show that Idexx Laboratories Inc is on a solid financial footing and is able to deliver value to its shareholders.

Idexx Laboratories Inc

Idexx Laboratories Inc: Achieving Remarkable Financial Success in Q3 2023

IDEXX Laboratories Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, reported its financial results for the third quarter of 2023, which ended on September 30. The company's revenue increased by 8.711% to $914.98 million compared to $841.66 million in the same period last year. This growth was driven by strong performance in the Companion Animal Group (CAG) and Water segments, with CAG revenue growing by 9% and Water revenue growing by 9%.
IDEXX also posted a significant increase in income, with a rise of 17.67% to $2.53 per share, compared to $2.15 per share in the prior year reporting period. The company's net income for the July to September 30 fiscal timeframe increased by 17.29% to $212.231 million, compared to net earnings of $180.938 million in the same period last year.

Idexx Laboratories Inc

Remarkable 9.655% Revenue Surge Propels Idexx Laboratories Inc to a Stellar Fiscal Performance; EPS Skyrockets by 71.15%



Idexx Laboratories Inc, a global leader in veterinary diagnostics and software solutions, has recently released its financial results for the second quarter of 2023. These results highlight the company's impressive growth in earnings per share (EPS) and revenue, as well as improvements in profit margins. In addition, the article will provide context by discussing Idexx Laboratories Inc's recent share performance.
Financial Results:
1. EPS Elevation: Idexx Laboratories Inc witnessed a significant increase in EPS of 71.15%, reaching $2.67 in the second quarter of 2023. This marks substantial growth compared to $2.55 per share in the prior reporting season.

Idexx Laboratories Inc

Very balanced improvement for the company amid the financial three months closing Mar 31 2023

Despite the positive financial results reported by Idexx Laboratories Inc in the first quarter of 2023, there are several reasons why investors should be cautious about investing in this company. Firstly, while the return on assets (ROA) has improved compared to the previous quarter, there are still three healthcare companies with a higher ROA. This suggests that Idexx may not be performing as well as some of its competitors in the industry.
Furthermore, while revenue and income per share have increased, it is important to note that this growth is lower than in the previous quarter. Revenue increased by 7.608% in the January to March 31 2023 span, compared to growth of 8.645% in the previous quarter. Similarly, income per share grew by 12.33% in the first quarter of 2023, compared to growth of 22.78% in the previous quarter. This suggests that the company's growth rate is slowing down, which could be a cause for concern.






 

Idexx Laboratories Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Idexx Laboratories Inc does not provide revenue guidance.

Earnings Outlook
Idexx Laboratories Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com